C
ENTA icon

Covestor’s Enanta Pharmaceuticals ENTA Stock Holding History

Covestor’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
24
+17
+243% +$228 ﹤0.01% 2567
2026
Q1 		$0 Sell
7
-8
-53% -$107 ﹤0.01% 2384
2025
Q4 		$0 Sell
15
-1
-6% -$13 ﹤0.01% 2371
2025
Q3 		$0 Hold
16
– – ﹤0.01% 2396
2025
Q2 		$0 Sell
16
-1
-6% -$6 ﹤0.01% 2338
2025
Q1 		$0 Buy
17
+13
+325% +$80 ﹤0.01% 2350
2024
Q4 		$0 Hold
4
– – ﹤0.01% 2356
2024
Q3 		$0 Hold
4
– – ﹤0.01% 2346
2024
Q2 		$0 Hold
4
– – ﹤0.01% 2357
2024
Q1 		$0 Sell
4
-1
-20% -$13 ﹤0.01% 2357
2023
Q4 		$0 Hold
5
– – ﹤0.01% 2269
2023
Q3 		$0 Buy
5
+1
+25% +$16 ﹤0.01% 2245
2023
Q2 		$0 Buy
4
+1
+33% +$29 ﹤0.01% 2257
2023
Q1 		$0 Hold
3
– – ﹤0.01% 2159
2022
Q4 		$0 Sell
3
-1
-25% -$46 ﹤0.01% 2188
2022
Q3 		$0 Buy
4
+1
+33% +$58 ﹤0.01% 2135
2022
Q2 		$0 Sell
3
-2
-40% -$109 ﹤0.01% 2029
2022
Q1 		$0 Sell
5
-1
-17% -$65 ﹤0.01% 2196
2021
Q4 		$0 Buy
+6
New +$471 ﹤0.01% 2169

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Covestor's ENTA Position: Q2 2026 in Review

Covestor increased its Enanta Pharmaceuticals (ENTA) stake by 243% in Q2 2026, buying an estimated $228 and bringing the position to 24 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2567.

Covestor first reported a position in ENTA in Q4 2021 and has held it in 19 quarters since. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • Covestor held 24 shares of Enanta Pharmaceuticals worth $0 as of Q2 2026.
  • Covestor bought 17 Enanta Pharmaceuticals shares in Q2 2026, an estimated $228.
  • Enanta Pharmaceuticals made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2567 holding.
  • Covestor first reported a position in Enanta Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
  • 123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.